Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 784

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 6
Chunk 784
---
     (8) 
     (277)
  
    Cash flows from financing activities: 

    Proceeds received from facility agreement 
     4,282  
     - 
  
    Repayment of facility agreement 
     (4,459) 
     - 
  
    Proceeds share issuance 
     48,343  
     - 
  
    Share issuance costs 
     (747) 
     - 
  
    Warrant issuance costs 
     (125) 
     - 
  
    Proceeds from issuance of convertible debt 
     2,779  
     - 
  
    Cancellation of warrants 
     (24,769) 
     - 
  
    Repayment of convertible debt 
     (3,795) 
     - 
  
    Debt issuance costs 
     (113) 
     - 
  
    Net cash provided by financing activities 
     21,396  
     - 
  
    Effect of exchange rate changes on cash and cash equivalents 
     306  
     (140)
  
    Net (decrease)/increase in cash and cash equivalents 
     8,875  
     (16,122)
  
    Cash and cash equivalents at beginning of period 
     5,858  
     22,120 
  
    Cash and cash equivalents at end of period 
     15,039  
     5,858 

    Non-cash investing and financing activities 

    Issuance of ELOC warrants at initial fair value 
     806  
     - 
  
    Issuance of convertible note warrants at initial fair value 
     341  
     - 
  
    Issuance of convertible rights at initial fair value 
     282  
     - 
  
    Issuance of Series A warrants at initial fair value 
     2,843  
     - 
  
    Partial conversion of convertible note 
     100  
     - 
  
    Total 
     4,372  
     - 

The accompanying notes are an integral part of
these consolidated financial statements.

F-6

INCANNEX HEALTHCARE INC.

Notes To Audited Consolidated Financial Statements

June 30, 2025 and 2024

Note 1 – Company Overview 

Incannex Healthcare Inc. (“Incannex”)
is a corporation formed